Regular Article
Characterization of Adiposity and Metabolism in Lmna-Deficient Mice

https://doi.org/10.1006/bbrc.2002.6466Get rights and content

Abstract

Dunnigan's Familial Partial Lipodystrophy (FPLD) is an autosomal dominant disease characterized by regional fat loss and insulin resistance. FPLD is caused by mutations in the LMNA gene, which encodes intermediate filaments of the nuclear lamina. Different LMNA mutations cause Emery–Dreifuss muscular dystrophy and/or a dilated cardiomyopathy. It is not known how LMNA mutations cause any of the disease phenotypes. Here we measure physical and metabolic characteristics of Lmna−/− and +/− mice to determine their usefulness as models for FPLD. Lmna−/− mice, which die prematurely of muscular dystrophy, have little fat, but do not show the insulin resistance characteristic of FPLD. Lmna+/− mice, despite treatment with a high fat diet, do not have decreased fat stores or metabolic features of FPLD. We also show, in mice, that Lmna transcripts are expressed at high levels in muscle and adipose tissue, but do not vary by body region or sex. In conclusion, Lmna+/− and −/− mice do not mimic Dunnigan's FPLD, and differential expression of lamins A and C does not appear to contribute to sex- or tissue-specific LMNA phenotypes.

References (28)

  • A. Garg et al.

    Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)

    J. Clin. Endocrinol. Metab.

    (1999)
  • M.G. Dunnigan et al.

    Familial lipoatrophic diabetes with dominant transmission. A new syndrome

    Q. J. Med.

    (1974)
  • J. Kobberling et al.

    Familial partial lipodystrophy: Two types of an X linked dominant syndrome, lethal in the hemizygous state

    J. Med. Genet.

    (1986)
  • Cited by (56)

    • Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement

      2019, Metabolism: Clinical and Experimental
      Citation Excerpt :

      To the best of our knowledge, there are mice models mimicking human FPLD2 – FPLD5, but not FPLD1 for which the specific mutation remains largely unknown. Knock out mice for LMNA A/C (LMNA−/−) or LMNA+/− do not demonstrate metabolic abnormalities [32,36], thus they do not mimic human FPLD2. In contrast, fat-specific expression of mutant lamin A or C leads to progressive partial lipodystrophy, which resembles the course of the disease observed in humans.

    • Lamins and Lamin-Associated Proteins in Gastrointestinal Health and Disease

      2018, Gastroenterology
      Citation Excerpt :

      Mice homozygous for these deletions have a phenotype similar to mice homozygous for LmnaSul/Sul, but die by 3 weeks rather than 8 weeks of age, indicating that the truncated LmnaSul gene product is partially functional.121,122 LmnaSul/Sul mice were initially reported to have no adipogenic or metabolic defects.123 However, subsequent studies with these mice,124 and with 2 separate lines of mice with different loss-of-function alleles,121,122 reported fat loss, impaired ex vivo adipogenesis, increased lipolysis in white adipose tissue, and impaired thermogenesis in brown adipose tissue in homozygous mice.

    • Hepatocyte-Specific Deletion of Mouse Lamin A/C Leads to Male-Selective Steatohepatitis

      2017, Cellular and Molecular Gastroenterology and Hepatology
    • Rapamycin Reverses Metabolic Deficits in Lamin A/C-Deficient Mice

      2016, Cell Reports
      Citation Excerpt :

      This implies that rapamycin enhances survival in Lmna−/− mice either through improvements in cardiac or skeletal muscle function, even though this was insufficient to affect survival in LmnaH222P/H222P mice, or through other unknown physiologic consequences, perhaps related to aspects of metabolism not phenocopied by thermoneutrality. Lmna−/− mice, used commonly as a model for the cardiomyopathy and muscular dystrophy associated with human mutations in LMNA (Schreiber and Kennedy, 2013; Zhang et al., 2013a), are also reported to be lean (Sullivan et al., 1999), and this has been speculated to be a consequence of their myopathic disease rather than lipodystrophy (Cutler et al., 2002). Here we show that Lmna−/− mice have elevated EE.

    • Functional architecture of the cell's nucleus in development, aging, and disease

      2014, Current Topics in Developmental Biology
      Citation Excerpt :

      All of these additional lines, that as homozygotes, develop overtly normally to birth. However, within the first 2 weeks of postnatal development, the homozygotes are growth retarded, with retardation being associated with defective skeletogenesis, skeletal hypomineralization (Li et al., 2011), immature muscle and heart development, together with metabolic complications associated with cachexia (Cutler et al., 2002). By 3 weeks, the homozygotes are dead, with the LmnaSul/Sul dying around 5–6 weeks, and which therefore express the mildest phenotype.

    View all citing articles on Scopus
    1

    To whom correspondence and reprint requests should be addressed at Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Building 10, Room 8N-250, 10 Center Drive, Bethesda, MD 20892-1770. Fax: (301) 402-5788. E-mail: [email protected].

    View full text